These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38698688)

  • 21. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.
    Fischer R; Breidert M; Keck T; Makowiec F; Lohrmann C; Harder J
    Saudi J Gastroenterol; 2012; 18(2):118-21. PubMed ID: 22421717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
    Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
    Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Cui QC; Shi J; Wang TX; You L; Shu H
    World J Surg; 2013 Jul; 37(7):1688-94. PubMed ID: 23568245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
    Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
    World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
    Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
    JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
    Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
    Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
    Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
    Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
    Merrell KW; Haddock MG; Quevedo JF; Harmsen WS; Kendrick ML; Miller RC; Hallemeier CL
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):561-70. PubMed ID: 26867884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
    Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
    J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
    Kurosaki I; Hatakeyama K
    Chemotherapy; 2005 Oct; 51(6):305-10. PubMed ID: 16224180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
    Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
    BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine.
    Numata K; Morinaga S; Katayama Y; Sawazaki S; Numata M; Godai T; Higuchi A; Shiozawa M; Rino Y; Masuda M; Akaike M
    Anticancer Res; 2016 May; 36(5):2467-74. PubMed ID: 27127159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.
    Wang P; Zhuang L; Zhang J; Fan J; Luo J; Chen H; Wang K; Liu L; Chen Z; Meng Z
    Mol Oncol; 2013 Jun; 7(3):334-45. PubMed ID: 23177026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
    Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
    Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
    Striefler JK; Sinn M; Pelzer U; Jühling A; Wislocka L; Bahra M; Sinn BV; Denkert C; Dörken B; Oettle H; Riess H; Bläker H; Lohneis P
    Pathol Res Pract; 2016 Aug; 212(8):726-34. PubMed ID: 27461834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
    Caponi S; Vasile E; Funel N; De Lio N; Campani D; Ginocchi L; Lucchesi M; Caparello C; Lencioni M; Cappelli C; Costa F; Pollina L; Ricci S; Mosca F; Falcone A; Boggi U
    Eur J Surg Oncol; 2013 Apr; 39(4):396-403. PubMed ID: 23290583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.